--- title: "Zai Lab released its annual performance, with total revenue of USD 399 million, an increase of 49.59% year-on-year" description: "Zai Lab released its annual performance for the year ending December 31, 2024, with total revenue of USD 399 million, a year-on-year increase of 49.59%. Research and development expenses amounted to U" type: "news" locale: "en" url: "https://longbridge.com/en/news/233527249.md" published_at: "2025-03-27T23:01:03.000Z" --- # Zai Lab released its annual performance, with total revenue of USD 399 million, an increase of 49.59% year-on-year > Zai Lab released its annual performance for the year ending December 31, 2024, with total revenue of USD 399 million, a year-on-year increase of 49.59%. Research and development expenses amounted to USD 235 million. The revenue growth was mainly attributed to the strong market launch of Weiwei Jia and its inclusion in the national medical insurance catalog, as well as sales growth of other products. The company expects revenue from existing and newly launched products to continue to grow in 2025, while the progress of each product pipeline is also ongoing According to the Zhitong Finance APP, Zai Lab (09688) announced its annual performance for the year ending December 31, 2024, with total revenue of USD 399 million, an increase of 49.59% year-on-year; R&D expenses amounted to USD 235 million. The announcement stated that the revenue growth was mainly due to the strong commercialization of Weiwei Jia since its launch in September 2023 and its inclusion in the national medical insurance catalog for the first time in January 2024, resulting in steady sales growth; Zele continued to maintain its leading position in the hospital sales of PARP inhibitors in the field of ovarian cancer; and benefited from the inclusion of the intravenous formulation and oral formulation of Niuzaili for the treatment of CABP and/or ABSSSI in the national medical insurance catalog in January 2023 and January 2024, respectively. Since the fourth quarter of 2024, with the group's launch of Weili Jia (the subcutaneous formulation of Efgartigimod) for the treatment of gMG and CIDP, Dingyoule for the treatment of HABP and VABP caused by ABC, and Aokail for the treatment of ROS1+ NSCLC in mainland China, the group has seen its commercialization portfolio increasingly strengthened. Aokail was included in the national medical insurance catalog in January 2025. In 2025, the group expects revenue from existing and recently launched commercial products to continue to grow. The group's product pipelines also continue to make progress. Regarding the group's global assets, the group achieved encouraging results in the global Phase I study of ZL-1310, a targeted DLL3 ADC with the potential to become a first-in-class and best-in-class treatment for extensive-stage small cell lung cancer. Additionally, the internally developed IL13/IL-31R bispecific antibody ZL-1503 for the treatment of atopic dermatitis has also obtained promising preclinical data. For the group's late-stage regional rights pipeline, the group obtained positive data this year, including KarXT for the treatment of schizophrenia, and completed enrollment in the second Phase III study of Bemarituzumab for the treatment of gastric cancer. The group has also expanded and strengthened its product pipeline with global and regional rights through synergistic business development, including a strategic cooperation and global licensing agreement with Yilian Biotechnology to utilize Yilian's TMALIN ADC platform to develop ZL-6201, a novel targeted LRRC15 ADC with the potential to become a first-in-class treatment, discovered by Zai Lab, for specific solid tumors, and a strategic cooperation with Vertex to obtain licensing for povetacicept (a potential best-in-class therapeutic drug for IgAN and other B cell-mediated diseases) in mainland China, Hong Kong, Macau, Taiwan, and Singapore ### Related Stocks - [ZLAB.US - Zai Lab](https://longbridge.com/en/quote/ZLAB.US.md) - [09688.HK - ZAI LAB](https://longbridge.com/en/quote/09688.HK.md) - [VERX.US - Vertex](https://longbridge.com/en/quote/VERX.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 再鼎医药将于 2 月 26 日召开董事会会议，以批准并公布 2025 年度业绩 | 再鼎医药有限公司已安排于 2026 年 2 月 26 日召开董事会会议，以批准截至 2025 年 12 月 31 日的经审计财务结果，符合美国通用会计准则（U.S. GAAP）。如果获得批准，结果将在同一天发布，并随后举行投资者电话会议。公 | [Link](https://longbridge.com/en/news/275665019.md) | | 中国批准再鼎医药的 AUGTYRO 用于治疗 NTRK 阳性实体瘤 | 再鼎医药有限公司已获得中国国家药品监督管理局（NMPA）对 AUGTYRO™（repotrectinib）的批准，用于治疗成人 NTRK 阳性实体瘤患者。该批准适用于局部晚期或转移性疾病的患者，这些患者在先前治疗后病情进展或缺乏令人满意的替 | [Link](https://longbridge.com/en/news/271650304.md) | | 智谱发布新一代旗舰模型 GLM-5，重点提升编程与智能体能力 | 2 月 11 日，智谱推出新一代旗舰模型 GLM-5，参数规模扩展至 744B，预训练数据达 28.5T，集成 DeepSeek 稀疏注意力机制。内部评估显示，其编程任务性能较上代提升超 20%，真实体验逼近 Claude Opus 4.5 | [Link](https://longbridge.com/en/news/275638705.md) | | AI 模型扎堆升级，国产算力需求狂飙，IDC 将迎来新一轮爆发？ | 美银指出，中国 AI 行业迎来关键转折：视频生成模型爆发将算力需求推升数个数量级，云服务与模型 API 全面涨价（智谱 AI 上调 30%、UCloud 全线调价），宣告价格战结束，定价权回归卖方。IDC 租赁价格企稳回升，世纪互联、万国数 | [Link](https://longbridge.com/en/news/275876097.md) | | 美国核电巨头 Holtec 申请 IPO，估值或超百亿美元 | Holtec 在核能领域深耕超过 40 年，将成为核能复兴浪潮中首家美国上市的成熟企业，其估值可能超过 100 亿美元，年收入超过 5 亿美元。除了反应堆重启，公司在核电站退役、小型模块化反应堆开发、乏燃料管理、热交换设备制造等多个领域占据 | [Link](https://longbridge.com/en/news/275534044.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.